The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A CONSORT-Compliant, Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Purified Anthocyanin in Patients With Nonalcoholic Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is a common liver disease that can progress to cirrhosis and liver failure. Anthocyanin, a member of the flavonoid family, has been shown to ameliorate NAFLD-associated pathologies in rodents.The aim of this CONSORT-compliant pilot study is to evaluate the effects of anthocyanin supplementation on insulin resistance and liver injury biomarkers in patients with NAFLD.A total of 74 subjects with NAFLD were divided into 2 groups in this double-blind, randomized study. Patients received either purified anthocyanin (320 mg/d) derived from bilberry and black currant or placebo for 12 weeks. Diet, physical activity, anthropometric parameters, glucose tolerance, and a set of biomarkers related to NAFLD were evaluated before and after intervention.No significant differences were observed in nutrient intake, physical activity, anthropometric parameters, or plasma lipid profile between patients receiving anthocyanin or placebo. Compared to controls, the anthocyanin group exhibited significant decreases (P < 0.05, all comparisons) in plasma alanine aminotransferase (-19.1% vs 3.1%), cytokeratin-18 M30 fragment (-8.8% vs 5.6%) and myeloperoxidase (-75.0% vs -44.8%). Significant decreases from baseline in fasting blood glucose and homeostasis model assessment for insulin resistance were observed in the anthocyanin group; however, these differences were not significant relative to placebo controls. In addition, the oral glucose tolerance test indicated that anthocyanin supplementation significantly decreased the 2-hour loading glucose level compared to control (-18.7% vs -3.8%, P = 0.02).A 12-week supplement of purified anthocyanin improved insulin resistance, indicators of liver injury, and clinical evolution in NAFLD patients. Further studies are warranted to determine the clinical applications of anthocyanin in NAFLD.This trial was registered at clinicaltrials.gov as NCT01940263.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anthocyanin supplementation (320 mg/day), a flavonoid, significantly improved insulin resistance and liver injury markers in patients with MASLD.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [215]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Prevalence and Control of Diabetes in Chinese Adults
Xu, Y. (2013) · JAMA · doi:10.1001/jama.2013.168118 · Cited by 2,710
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
The prevention and treatment of missing data in clinical trials
Little, R. J., D'Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., Frangakis, C., Hogan, J. W., Molenberghs, G., Murphy, S. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmsr1203730 · Cited by 1,884
Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women
Mink, P. J., Scrafford, C. G., Barraj, L. M., Harnack, L., Hong, C.-P., Nettleton, J. A., & Jacobs, D. R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.3.895 · Cited by 945
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States
Younossi, Z. M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B. P., & Srishord, M. K. (2012) · Medicine · doi:10.1097/md.0b013e3182779d49 · Cited by 554
Dietary flavonoid intakes and risk of type 2 diabetes in US men and women
Wedick, N. M., Pan, A., Cassidy, A., Rimm, E. B., Sampson, L., ROSNER, B. A., Willett, W. C., Hu, F. B., Sun, Q., & van Dam, R. M. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.028894 · Cited by 527
Cited by
Sorted by citations
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
Guasch-Ferré, M., Merino, J., Sun, Q., Fitó, M., & Salas-Salvadó, J. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/6723931 · Cited by 297
Salomone, F., Godos, J., & Zelber‐Sagi, S. (2015) · Liver International · doi:10.1111/liv.12975 · Cited by 261
Saleh, H. A., Yousef, M. H., & Abdelnaser, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.606069 · Cited by 269
Metadata
- Authors
- Zhang, P.-W., Chen, F.-X., Li, D., Ling, W.-H., & Guo, H.-H.
- Affiliations
- Sun Yat-sen University (CN)
- ORCID
- Li, Di
- Venue
- Medicine
- Published
- 2015-05
- Volume
- 94
- Issue
- 20
- Pages
- e758
- ISSN
- 0025-7974 (ISSN-L)
- PMC
- PMC4602870
- OpenAlex
- W2301998872
- Cited by
- 116
- References
- 40
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 11 · 2023: 18 · 2022: 7 · 2021: 20 · 2020: 12 · 2019: 10 · 2018: 11 · 2017: 8 · 2016: 2 · 2015: 3
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2012CB517506)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Biochemistry (medical) › Phytochemicals and Antioxidant Activities
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- non-alcoholic fatty liver disease, anthocyanins, Vaccinium myrtillus, black currant, flavonoids, dietary supplementation, insulin resistance, liver injury biomarkers, alanine aminotransferase, myeloperoxidase, oral glucose tolerance, fasting blood glucose
- MeSH terms
- Adult, Anthocyanins, Cholesterol, Double-Blind Method, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Lipoproteins, LDL, Male, Middle Aged, Pilot Projects, Triglycerides, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review